Skip to main content

Advertisement

Table 1 Selected patient and tumor characteristics

From: Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group

Characteristics Total (N = 819)
N (%)
Age (in years)
 <50 348 (42.5)
 ≥50 471 (57.5)
NPI score
 Median (range) 5.52 (3.0–9.0)
Treatment group
 E-CMF 123 (15.0)
 E-T-CMF 392 (47.9)
 ET-CMF 304 (37.1)
Menopausal status
 Premenopausal 375 (45.8)
 Postmenopausal 444 (54.2)
Breast surgery
 Modified radical mastectomy 579 (70.7)
 Breast-conserving surgery 240 (29.3)
ER/PgR status
 Negative 165 (21.7)
 Positive 596 (78.3)
Histological grade
 I–II 406 (49.6)
 III–Undifferentiated 413 (50.4)
Tumor size (cm)
 ≤2 181 (22.8)
 2–5 517 (65.2)
 >5 95 (12.0)
Positive lymph nodes
 1–3 nodes 331 (40.5)
 ≥4 nodes 487 (59.5)
Adjuvant radiation therapy
 No 184 (23.2)
 Yes 609 (76.8)
Adjuvant hormonal therapy
 No 154 (18.9)
 Yes 661 (81.1)
Bone metastases
 No 711 (88.4)
 Yes 93 (11.6)
HER2 status
 Negative 593 (76.5)
 Positive 182 (23.5)
Ki67 protein expression
 Low (<20%) 367 (44.8)
 High (≥20%) 452 (55.2)
Subtypes
 Luminal A 245 (32.3)
 Luminal B 248 (32.8)
 Luminal-HER2 99 (13.1)
 HER2-enriched 79 (10.4)
 Triple-negative 86 (11.4)
OPN mRNA expression
 Low (<50th percentile) 407 (50.0)
 High (≥50th percentile) 407 (50.0)
OPN protein expression
 Low (0–4 Allred score) 59 (10.8)
 High (5–8 Allred score) 487 (89.2)